Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04332926 · ClinicalTrials.gov registry record · NA
Effects of E-Cigarette Nicotine Content in Smokers (Nicotine Flux Study)
A NA study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- NA
- Development phase
- 44
- Enrollment target
NCT04332926: Completed NA study, sponsored by Virginia Commonwealth University.
NCT04332926 is a NA study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 44 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04332926, a NA study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- NA
- Development phase
- 44 participants
- Enrollment target
Study Summary
This study aims to better understand how e-cigarettes (ECIG) nicotine flux impacts several behavioral economic measures of abuse liability.
Primary Outcome
This is now a single-arm parallel study design. The main outcome of interest in the CP-PRT is the relative reinforcing value - defined as how hard a participant is willing to work for the session product compared to their own brand cigarette. The breakpoint, or highest trial number that a participant completed for a puff of the session-specific product will be used as the measure of relative reinforcing value.
Interventions
- OTHER Tobacco product administration and assessment, own brand cigarettes
- OTHER Tobacco product administration and assessment, ECIG 30 Watts, 0 mg/ml nicotine
- OTHER Tobacco product administration and assessment, ECIG 30 Watts, 8 mg/ml nicotine
- OTHER Tobacco product administration and assessment, ECIG 30 Watts, 15 mg/ml nicotine
- OTHER Tobacco product administration and assessment, ECIG 30 Watts, 30 mg/ml nicotine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2021-01-05 |
| Est. Completion | 2023-09-08 |
| Phase | NA |
What the finished NCT04332926 record still lists
NCT04332926 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 5 interventions - of which Tobacco product administration and assessment, own brand cigarettes is the first listed.
NCT04332926 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04332926 about?
NCT04332926 is a clinical study titled "Effects of E-Cigarette Nicotine Content in Smokers (Nicotine Flux Study)". This study aims to better understand how e-cigarettes (ECIG) nicotine flux impacts several behavioral economic measures of abuse liability.
What is the current status of trial NCT04332926?
This trial is currently completed. It is a NA study. The enrollment target is 44 participants. The study started on 2021-01-05. Estimated completion is 2023-09-08.
What interventions are being tested in trial NCT04332926?
The interventions under investigation include: Tobacco product administration and assessment, own brand cigarettes (OTHER), Tobacco product administration and assessment, ECIG 30 Watts, 0 mg/ml nicotine (OTHER), Tobacco product administration and assessment, ECIG 30 Watts, 8 mg/ml nicotine (OTHER), Tobacco product administration and assessment, ECIG 30 Watts, 15 mg/ml nicotine (OTHER), Tobacco product administration and assessment, ECIG 30 Watts, 30 mg/ml nicotine (OTHER).
Who is sponsoring clinical trial NCT04332926?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04332926's enrollment target sits among peer trials
44 1423rd of 2000 higher than 566 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI